Optimising Drug Development by Modelling and Simulation Approaches

ODDMS is a project is funded by the Hellenic Foundation for Research and Innovation (ELIDEK) under the “First Call for H.F.R.I. Research Projects to support Faculty members and Researchers and the procurement of high-cost research equipment grant” (Project Number: 1058)

Budget: 180 000 €,  duration: 42 months, official start date: 13/2/2020.

Project summary

In a wide range of scientific and industrial applications, from weather forecasting to heavy industries, Modeling and Simulation (M&S) is an approach which uses computational models developed from scientific knowledge and collected data, in order carry out simulations for scenarios where data is sparse, or non-existent. In the last two decades M&S has found significant applications in all phases of drug development and has created the new field of pharmacometrics. Pharmacometrics relies on building mathematical models which describe the pharmacokinetics and pharmacodynamics of drugs, as well as the variability of the corresponding model parameters. Project ODDMS deals with the application of M&S methodologies in drug development, by focusing on 3 categories of products of particular interest to the Greek pharmaceutical Industry, and aims to produce (a) methodological advances in the way these products are developed by the industry and approved by the authorities and (b) produce specific new results for the application of the particular products studied. The proposed case studies are: (a) Absorption and pharmacokinetics of Long Acting Injectable products by Population pharmacokinetic modeling. (b) Gastrointestinal drug absorption by Physiologically Based Pharmacokinetic (PBPK) models targeting in-silico bioequivalence studies. (c) Pharmacokinetics, efficacy and safety of radiopharmaceuticals by PBPK models developed from imaging data. For these studies specific pharmaceutical products will be used as case studies. The products studied are supported by significant amounts of quality datasets, which will be offered by Greek pharmaceutical companies. The main work will be undertaken by 3 PhD students, who will be trained at the highest level in the rapidly growing field of pharmacometrics with great career prospects and in collaboration with experts from Greece and abroad.


  • Aris Dokoumetzidis (PI)
  • Iasonas Kapralos (PhD student)
  • Evangelos Karakitsios (PhD student)
  • Christos Kaikousidis (PhD student)


New publication for WP3:

Kaikousidis C, Dokoumetzidis A. In Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data. Pharm Res. 2022 doi: 10.1007/s11095-022-03412-w. https://link.springer.com/article/10.1007/s11095-022-03412-w

First publication for WP1:

Kapralos I, Dokoumetzidis A. Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis. Pharmaceutics. 2021 Sep 28;13(10):1578. doi: 10.3390/pharmaceutics13101578. https://www.mdpi.com/1999-4923/13/10/1578